Literature DB >> 6628523

Estimation of the absolute oral bioavailability of pindolol by two analytical methods.

M Guerret, G Cheymol, J P Aubry, A Cheymol, D Lavene, J R Kiechel.   

Abstract

The absolute oral bioavailability of pindolol has been estimated by two analytical methods, fluorimetry and GLC-ECD. The study was carried out in six healthy subjects who received either i.v. or oral pindolol in random order. The results obtained by both methods were similar and confirm the high bioavailability (about 75%) of pindolol. The present findings are compared with previous publications and emphasize the importance of undertaking bioavailability studies in the same subjects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628523     DOI: 10.1007/bf01037948

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.

Authors:  D Lavene; Y A Weiss; M E Safar; Y Loria; N Agorus; D Georges; P L Milliez
Journal:  J Clin Pharmacol       Date:  1977 Aug-Sep       Impact factor: 3.126

2.  Pharmacokinetics of pindolol in man.

Authors:  R Gugler; W Herold; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

3.  Simultaneous tubular excretion and reabsorption of pindolol in man.

Authors:  L Balant; K Muir; P Dayer; A Gorgia; J L Eberlin; J Estreicher; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Determination of pindolol in biological fluids by an electron-capture gas-liquid chromatographic method on a wall-coated open tubular column.

Authors:  M Guerret
Journal:  J Chromatogr       Date:  1980-12-12

5.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

6.  Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia.

Authors:  G L Jennings; A Bobik; E T Fagan; P I Korner
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

  6 in total
  2 in total

Review 1.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

2.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.